Global Information
회사소개 | 문의

중국의 몬테루카스트(Montelukast) 시장

Investigation Report on China´s Montelukast Market, 2018-2022

리서치사 China Research and Intelligence
발행일 2018년 11월 상품 코드 296860
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,506,600 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,760,000 Printable & Editable PDF (Enterprisewide License)


중국의 몬테루카스트(Montelukast) 시장 Investigation Report on China´s Montelukast Market, 2018-2022
발행일 : 2018년 11월 페이지 정보 : 영문 30 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

중국 국내에는 현재 천식 환자가 3,000만 명, 알레르기성 비염 환자가 3,000∼4,000만 명 존재하고 있으며, 환경오염 악화와 함께 환자수는 더욱 증가할 전망입니다. 몬테루카스트는 최적의 항천식약 중 하나로 생각되고 있습니다. 2005년 출시부터 2010년까지 중국의 몬테루카스트 시장은 CAGR 45%로 급성장했습니다. 경쟁사가 참여한 이후 성장률은 하락했지만, 그럼에도 불구하고 연간성장률 10%를 유지하고 있어 거대한 잠재적 시장임을 나타내고 있습니다.

중국의 몬테루카스트(Montelukast) 시장을 분석하고, 중국 국내에서의 생산 및 병원용 매출액·가격 동향(과거 5년간), 기업별·투약 형태별 시장 점유율, 주요 제조업체 개요, 향후 시장 동향 전망(향후 5년간) 등의 조사 결과를 전해드립니다.

제1장 몬테루카스트 관련 개념

  • 정의
  • 증상
  • 세계 시장에서의 판매 상황

제2장 중국의 몬테루카스트 시장 개요

  • 특허 현황
  • 주요 제조업체
  • 시장 규모

제3장 몬테루카스트 매출액 분석

  • 매출액
  • 판매량

제4장 주요 제조업체의 시장 점유율 분석

  • 시장 점유율(금액 기준)
  • 시장 점유율(수량 기준)

제5장 제형별 시장 규모 분석

  • 제형별 시장 점유율(금액 기준)
  • 제형별 시장 점유율(수량 기준)

제6장 몬테루카스트의 병원용 기준가격(기업별)

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)
  • Merck Shark. Dohme, MSD(UK)

제7장 주요 제조업체 분석

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)

제8장 중국의 몬테루카스트 시장 전망

  • 시장 규모 예측
  • 시장 경쟁 예측

도표

KSM 14.03.13

Description

More than 300 million people in the world are suffering from seasonal asthma of varying degrees. The number is higher in countries with severe environmental pollution and high tobacco consumption. Asthma and allergic rhinitis are common nowadays. Owing to heavy air pollution, the incidences of these diseases are increasing year by year.

Montelukast, developed by MSD, is widely used in the treatment of allergic rhinitis and asthma. As a selective leukotriene D4 receptor antagonist, it selectively binds to the leukotrienes in the airway, blocks the action of allergic mediators, reduces airway inflammation, and makes the airway unobstructed. In 1998, Montelukast sodium tablets (10 mg) and chewable tablets (5 mg) were approved by the FDA and first marketed in the U.S. in the trade name of "Singulair". In 2000 and 2002, Montelukast chewable tablets (4 mg) and granules (4 mg) were approved for sale, mainly for the prevention and long-term treatment of asthma in adults and children aged above 2.

In 1999, MSD's Montelukast chewable tablets (5mg) and tablets (10mg) were approved to enter China in the trade name of "Singulair", followed by Montelukast chewable tablets (4mg) and granules (4mg). In 2006, the generic Montelukast tablets (10mg) and chewable tablets (5mg) by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to be sold in the trade name of "Bystine". Many other companies in China have also filed applications for generic Montelukast.

According to CRI's market research, from 2005 to 2010, the annual sales value of Montelukast in China grew at a CAGR of more than 40%. As competing products emerged, the growth rate slowed down from 2011 but stays above 10%. In 2017, the market size of Montelukast was about CNY 552 million. The market was dominated by MSD, Lunan Better Pharmaceutical Co., Ltd., and Sichuan Otsuka Pharmaceutical Co., Ltd. Declining in recent years, the market share by sales value of MSD was close to 73%.

According to statistics, there are more than 30 million asthma patients and 300 million to 400 million patients with allergic rhinitis in China. And the numbers will continue to rise with increasingly serious environmental pollution. In China, Montelukast is considered as one of the best anti-asthmatic drugs, which promises huge market potential.

Topics Covered:

  • Situation of respiratory diseases in China
  • Supply and sales of Montelukast in China
  • Prices of Montelukast in China
  • Competition on China's Montelukast market
  • Market share of Montelukast manufacturers in China
  • Prospect of China's Montelukast Market, 2018-2022

Table of Contents

Table of Contents

1 Basic Concept of Montelukast

  • 1.1 Indications for Montelukast
  • 1.2 Development of Montelukast in China
  • 1.3 Government Approval of Montelukast in China

2 Sales of Montelukast in China, 2013-2017

  • 2.1 Sales Value of Montelukast
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Montelukast
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Montelukast by Dosage Form in China, 2013-2017
    • 2.3.1 Tablets
    • 2.3.2 Granules

3 Analysis on Major Montelukast Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Montelukast Manufacturers 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 MSD
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of MSD's Montelukast in China
  • 3.3 Lunan Better Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast in China
  • 3.4 Sichuan Otsuka Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast in China

4 Prices of Montelukast in China, 2017-2018

  • 4.1 MSD (Singulair)
  • 4.2 Lunan Better Pharmaceutical Co., Ltd. (Pingqi)
  • 4.3 Sichuan Otsuka Pharmaceutical Co., Ltd. (Bystine)

5 Prospect of China's Montelukast Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Governmental Approval of Montelukast in China
  • Chart Sales Value of Montelukast in China, 2013-2017
  • Chart Sales Value of Montelukast in Parts of China, 2013-2017
  • Chart Sales Volume of Montelukast in China, 2013-2017
  • Chart Sales Volume of Montelukast in Parts of China, 2013-2017
  • Chart Sales Value of Montelukast Tablets in China, 2013-2017
  • Chart Sales Value of Montelukast Granules in China, 2013-2017
  • Chart Market Share by Sales Value of Top 3 Montelukast Manufacturers, 2013-2017
  • Chart Market Share by Sales Volume of Top 3 Montelukast Manufacturers, 2013-2017
  • Chart Sales Value of MSD's Montelukast, 2013-2017
  • Chart Sales Volume of MSD's Montelukast, 2013-2017
  • Chart Sales Value of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Sales Volume of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Sales Value of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Sales Volume of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast, 2013-2017
  • Chart Prices of MSD's Montelukast in Parts of China, 2017-2018
  • Chart Prices of Lunan Better Pharmaceutical Co., Ltd.'s Montelukast in Parts of China, 2017-2018
  • Chart Prices of Sichuan Otsuka Pharmaceutical Co., Ltd.'s Montelukast in Parts of China, 2017-2018
  • Chart Forecast on Sales Volume of Montelukast in China, 2018-2022
Back to Top
전화 문의
이용안내
 
BCC Research